VC-backed Arvinas goes public
New Haven, Connecticut-based Arvinas Inc, a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases, has raised about $120 million after pricing its IPO of 7.5 million shares at $16 per share. The stock began trading September 27, 2018 on the NASDAQ under the ticker symbol “ARVN." Goldman Sachs, Citigroup and Piper Jaffray & Co are the lead underwriters. Arvinas' pre-IPO backers included Nextech Invest, Deerfield Management, Hillhouse Capital, Sirona Capital, Canaan Partners, 5AM Ventures, RA Capital Management, OrbiMed and New Leaf Venture Partners.
27 September 2018•3 mins read
